Bank of America Reiterates “Neutral” Rating for Sarepta Therapeutics (NASDAQ:SRPT)
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at Bank of America in a research report issued on Monday, MarketBeat Ratings reports. They currently have a $28.00 target price on the biotechnology company’s stock, down from their previous target price of $76.00. Bank of America‘s target price […]
Sarepta Therapeutics (NASDAQ:SRPT – Get Free Report)‘s stock had its “neutral” rating reaffirmed by stock analysts at Bank of America in a research report issued on Monday, MarketBeat Ratings reports. They currently have a $28.00 target price on the biotechnology company’s stock, down from their previous target price of $76.00. Bank of America‘s target price […]
